Lumida
/FHTX
⌘K
Foghorn Therapeutics Inc

Foghorn Therapeutics Inc

FHTX
$4.42USD↓-1.56%-0.07 today

MARKET CAP

262.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $5

52W RANGE

$3
$8

AI Summary

Stalk
TrimMedium

FHTX remains in a prolonged Stage 4 decline under sustained lower highs and lower lows with EMAs sloping downward and acting as resistance. The active Bearish Exhaustion pattern signals sellers losing control and increases the probability of a bottoming attempt or reversal bounce. Despite extreme oversold readings, lack of sustained reversal suggests selling is best deferred. Favor trimming on rallies into declining EMA regions or prior support-turned-resistance zones for structurally aligned execution.

  • ↑Q2 collaboration revenue rose to $16.1M from $7.6M last year.
  • ↑Net loss shrank to $7.2M from $17.9M as R&D expenses fell to $18.5M.
  • ↓Profitability remains weak, failing to convert revenue into profit.
Full analysis →

Buying

4

institutions

Selling

4

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY2.63 M12.82 M+261.97 K+13.4%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL377.94 K1.84 M+-28.49 K-5.1%0.00%
WP

Woodline Partners LP

Q2 2026

SELL202.15 K986.47 K+-158.52 K-42.8%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL158.82 K775.05 K+-41.19 K-18.9%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY66.24 K323.25 K+33.68 K+107.7%0.00%
MM

Millennium Management LLC

Q2 2026

BUY53.51 K261.12 K+23.96 K+84.8%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY20.43 K99.30 K+1.75 K+20.2%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

SELL0.000.00+-27.65 K-100.0%0.00%